CV Sciences, Inc. (CVSI) Form 10-Q — Aug 13, 2026
CV Sciences filed its 10-Q for the quarter ended June 30, 2026, reporting net product sales of $3.0 million, down 17.5% year over year, with the quarterly net loss widening to $775,000 from $261,000 a year earlier. Management blamed lower sales volume from restrictive state regulations, out-of-stock issues on key products, and reduced third-party contract manufacturing revenue. The filing carries explicit going-concern language: the company's operating results and $89.4 million accumulated deficit raise substantial doubt about its ability to continue as a going concern, and it held just $266,000 in cash at quarter end against roughly $4.9 million in current liabilities.
Key figures
- Eps
- -0.00 (Q2 2026 basic/diluted); -0.01 (six months 2026)
- Revenue
- 2985000
- Revenue Yoy
- -17.5% (Q2 2026 vs Q2 2025); -14.5% six months
- Total Assets
- 6521000
- Cash Position
- 266000
- Shares Outstanding
- 225829128
- Six Month Revenue
- 6180000
- Q2 Notes Converted
- 705998
- Units Sold Change Q2
- -14.9%
- Gross Margin Q2 2025
- 50.9%
- Gross Margin Q2 2026
- 48.6%
- Stockholders Equity
- 1571000
- Third Notes Issued Q2
- 366090
- Fixed Conversion Price
- $0.03 (cut from $0.06 in April 2026)
- Six Month Notes Converted
- 1257684
- Gross Margin Six Months2026
- 48.7%
- Weighted Avg Shares Q2 2026
- 205086000
- Convertible Notes Fair Value
- 1017000
- Q2 Shares Issued On Conversion
- 19664108
- Anti Dilutive Securities Total
- 93839000
- Amended Notes Aggregate Principal
- 2256000
- Six Month Shares Issued On Conversion
- 28858865
- Third Notes Issued Subsequent To Quarter
- 71811
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.